Premark Pharma Management
Ian Vessey Managing Director
Has 30 years of pharma industry experience, including 15 years working in global strategic marketing roles, mostly operating at the clinical-commercial interface. This included 4 years as Head of Early Phase Marketing for the Novartis Ophthalmics Business Unit, which exposed him to all the major eye markets, including blepharitis and dry eye.
He was invited to join the International Dry Eye Workshop, contributing to the 2007 publication of the same name. During this time he also led the Lucentis Launch Readiness project for wet AMD across Europe.
He founded Premark Pharma in April 2018 and sits on the Board of Directors.
Friedrich K. Mayer Head of Development
Has 45 years experience in the pharmaceutical industry. Starting in the Sandoz Research Institute in Vienna he moved to corporate headquarters in Basel, Switzerland (now Novartis) as Global Project Leader. He built and led multidisciplinary global project teams taking 6 NMEs from research through registration to life cycle management, including more than 10 years leading the Elidel (pimecrolimus) project in atopic dermatitis.
After retiring from Novartis he has worked as a consultant to small biotechnology firms.
Friedrich has extensive experience in dermatology, infectious diseases and immunology. He holds a Dr. sc. (chemistry) from the University of Technology in Vienna, Austria and an MBA from INSEAD in Fontainebleau, France.
Prof. Dr. Thomas Reinhard
Medical Director, Eye Center, University Hospital Freiburg, Germany
Prof. Dr. Daniel Böhringer
Head of Clinical Trials Group, Eye Center, University Hospital Freiburg, Germany
William Stewart MD
Medical Director PRN Pharmaceutical Research Network, LLC
Director PRN PharmaFarm, LLC